The Medicines Company (NASDAQ:MDCO) will present new data from studies involving the investigational lipid-modifying agent MDCO-216 and investigational intravenous antiplatelet agent cangrelor during the annual American Heart Association (AHA) Scientific Sessions in Chicago, November 15-19. The oral presentations and abstracts involve clinical data and analyses from two core areas of cardiovascular medicine for the Company: lipid-modifying therapies and acute cardiovascular care.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
